Artivion announces treatment of first patient in ARTIZEN pivotal trial

Artivion (AORT) announced the treatment of the first patient in the ARTIZEN pivotal trial, evaluating the safety and effectiveness of the Arcevo LSA Hybrid Stent Graft System in the treatment of acute and chronic arch pathologies. The trial is designed to support the company’s forthcoming application to the U.S. FDA for Premarket Approval of Arcevo LSA. “We estimate a PMA for Arcevo would open an incremental $80 million U.S. market opportunity as soon as 2029.”